vTv Therapeutics closed at $24.03 on Nov 4, up 2.04%, within 2.7% of its 52-week closing low. Volume of 28.6K shares was 1.30× its 20-day average (above normal).
Split-adjusted performance: -20.0% over one month, -24.1% over six months, +2.7% over one year.
Short interest was 143.4K shares at the Oct 15 settlement, down 8.5% from the prior report (9.7% of float, 5.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| VTVTvTv Therapeutics | $24.03 | +2.04% | −24.1% | — | — | — | $95.0M | |
| PDSBPDS Biotechnology | $1.30 | −7.80% | +22.6% | — | — | — | $94.2M | Compare |
| MISTMilestone Pharmaceuticals | $0.7725 | +1.74% | −60.8% | — | −5118.8% | — | $96.2M | Compare |
| NTHINeOnc Technologies Holdings | $3.17 | +3.26% | −40.3% | — | — | — | $91.3M | Compare |
| CATXPerspective Therapeutics | $0.8702 | −1.11% | −77.2% | −72.1% | −33069.1% | — | $99.3M | Compare |
| PLYXPolaryx Therapeutics | $1.80 | +4.05% | −52.6% | — | — | — | $89.7M | Compare |
| GNLXGenelux | $1.96 | +2.08% | −31.7% | — | — | — | $88.7M | Compare |
| TNXPTonix Pharmaceuticals Holding | $5.11 | −1.54% | −65.2% | +577.9% | −299.4% | — | $87.6M | Compare |
| UNCYUnicycive Therapeutics | $3.75 | +4.46% | −53.9% | — | — | — | $104.5M | Compare |
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
